Clinical Trial Concierge Web Page Launch
The NMD4C are excited to announce that the new clinical trial (CT) Concierge web page is now live!
The role of the CT Concierge is to act as an information broker for clinical trials for all Canadian clinical care sites and to support the NMD4C community with consistent knowledge, awareness, and access to information across sites.
This position is independently objective and designed to serve as an impartial resource, not funded by industry and is for all NM stakeholders.
The Concierge role was created to strengthen the clinical trial landscape and be a resource to all key stakeholders. A key priority of the concierge will be to work with Investigators to develop solutions to barriers associated with bringing neuromuscular clinical trials to Canada.
Visit the Concierge web page here, and discover the benefits of working with the Concierge for investigators, patients and families, industry, and other stakeholders.
Read next...
Applications Open for New NMD4C Collaborative Research Training Awards!
The NMD4C is excited to announce a new program for neuromuscular research trainees that will support collaboration opportunities between Canadian research labs.
NMD4C Members Receive Dr David Green Awards from Muscular Dystrophy Canada
We are excited to share that several NMD4C investigators and members have been honored with a Dr David Green Award from Muscular Dystrophy Canada!
Lower Extremity Muscle Strengthening Program in Myotonic Dystrophy Type 1 from Groupe de recherche interdisciplinaire sur les maladies neuromusculaires
The Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) recently created a video aimed at health professionals that provides an in-depth explanation of the Myotonic dystrophy (DM1) training parameters used in their studies.
Fifth Annual Clinical Fellowship Competition from NMD4C and MDC Opens May 1st
The NMD4C and MDC clinical neuromuscular fellowship competition is accepting applications for the 2026 competition until June 12, 2025.
